• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The American journal of Chinese medicine >Sairei-to therapy on alloimmune recurrent spontaneous abortions and alloimmune-, autoimmune complicated recurrent spontaneous abortions.
【24h】

Sairei-to therapy on alloimmune recurrent spontaneous abortions and alloimmune-, autoimmune complicated recurrent spontaneous abortions.

机译：对同种免疫反复自然流产和同种免疫，自身免疫复杂的反复自然流产的Sairei-to治疗。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Alloimmune recurrent spontaneous abortion (RSA) cases that could not be treated with lymphocyte transfusion due to medical and social reasons were treated with Sairei-to therapy as an emergency measure and all four cases resulted in live births. This may show that Sairei-to treatment is effective in preventing alloimmune RSA. The efficacy of Sojyutsu-Sairei-to and Byakujyutsu-Sairei-to on autoimmune RSA has already been proven. When they were used in the treatment of alloimmune-, autoimmune complicated RSA, the abortion prevention rates were 65.4% and 82.3% respectively. These results indicate that Sairei-to is effective in the treatment of alloimmune RSA and alloimmune-, autoimmune complicated RSA.
机译：由于医学和社会原因无法通过淋巴细胞输注治疗的同种免疫复发性自然流产（RSA）病例采用Sairei-to治疗作为紧急措施，所有四例均导致了活产。这可能表明Sairei-to治疗可有效预防同种免疫RSA。 Sojyutsu-Sairei-to和Byakujyutsu-Sairei-to对自身免疫性RSA的功效已得到证实。当用于同种免疫，自身免疫的复杂RSA治疗时，流产预防率分别为65.4％和82.3％。这些结果表明，Sairei-to可有效治疗同种免疫RSA和同种免疫，自身免疫性复杂RSA。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号